Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Mehta et al. — ctDNA in Urothelial Carcinoma SR
PMID: 42262988 | Triage Score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First unified ctDNA integration framework across all UC stages; TERT mutation dominance and specific detection rates (53–86%) by stage are new synthesized benchmarks |
| Clinical Relevance | 8 | Directly actionable across NMIBC surveillance, MIBC adjuvant decisions, and mUC monitoring; HR 6.3 post-surgery OS data has immediate clinical significance |
| Population Reach | 6 | ~600K new UC diagnoses/year globally; bladder cancer is the 6th most common in the US; affects both sexes but male-predominant |
| Implementation Speed | 7 | ctDNA testing infrastructure already exists; systematic review synthesizes existing evidence; clinical integration framework ready for protocol adoption |
| Evidence Strength | 7 | 61-study systematic review with specific quantitative outcomes; not a meta-analysis with pooled statistics, but breadth and stage stratification are robust |
Key quantitative result: HR 6.3 for OS in ctDNA-positive post-surgery patients (IMvigor010); 94–100% sensitivity for recurrence detection with 96–131 day lead time.
External validation: Multiple independent studies synthesized including KEYNOTE-361 and IMvigor010 — multi-trial cross-validation is implicit.
Main limitation: Abstract-only access; no pooled meta-analytic statistics; heterogeneity across 61 studies in ctDNA platforms, variant panels, and clinical endpoints likely high.
Equity implications: ctDNA testing access heavily favors high-income settings; patients in low/middle-income countries with high UC burden (occupational exposures, endemic schistosomiasis) may not benefit. Integration framework is largely designed for health systems with genomic infrastructure.
Evidence Maturity Confirmation: ✅ Validated — synthesizes mature evidence across multiple RCT subsets and observational cohorts with quantitative endpoints.
Article 2 — Kugiyama et al. — Bile exosomal miR-196a/-196b in BTC
PMID: 42261877 | Triage Score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First validation of bile-derived (not plasma) exosomal miRNA biomarkers for BTC; proximity advantage of bile over blood is a mechanistically compelling distinction |
| Clinical Relevance | 7 | BTC is typically diagnosed at late stage; early-stage miR-196a signal directly addresses a critical unmet need; AUROC 0.88 with CA19-9+CEA is clinically meaningful |
| Population Reach | 5 | BTC is rare (globally ~210K/year) but carries very high mortality; relative to the affected clinical population and unmet need, impact is high |
| Implementation Speed | 4 | Bile sampling requires ERCP or biliary drainage procedure — not trivially implementable; requires further validation before clinical rollout |
| Evidence Strength | 6 | Multi-cohort design (training n=20, validation n=103, serum n=143) is credible; TaqMan PCR validation is standard; Japanese single-country cohort limits generalizability |
Key quantitative result: miR-196a AUROC 0.79 alone; 0.86 with CA19-9; 0.88 with CA19-9+CEA. Early-stage BTC signal specifically noted.
External validation: Internal training + independent validation cohort design provides reasonable within-study validation; no external international replication yet.
Main limitation: Bile collection requires invasive biliary access (ERCP) — a significant practical barrier. Japanese population only; no Western or Southeast Asian cohort validation. Functional cell line data is supportive but not essential to diagnostic claim.
Equity implications: ERCP-based bile sampling is resource-intensive; this biomarker is most accessible in tertiary centers with advanced biliary endoscopy, potentially widening gaps for rural or lower-income populations where BTC is actually more prevalent (East/Southeast Asia, parts of Africa).
Evidence Maturity Revision: ⬇️ Exploratory → Validated (conditional) — multi-cohort human design justifies "Validated" designation for the diagnostic signal, but the procedural barrier and single-country limitation place it closer to late-stage exploratory pending broader validation.
Article 3 — HER2-mutant NSCLC Japan Nationwide Database
PMID: 42263332 | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Real-world data on an approved therapy; adds real-world benchmarks post-T-DXd approval but does not introduce new science |
| Clinical Relevance | 7 | Real-world ORR/DCR benchmarks for T-DXd in HER2-mutant NSCLC directly inform clinical expectations and guideline committees |
| Population Reach | 5 | HER2 mutations occur in |
| Implementation Speed | 7 | T-DXd is already approved; these data refine patient selection and expectations without requiring new infrastructure |
| Evidence Strength | 5 | Large n=3,012 but retrospective database study; medium classification_confidence due to truncated retrieval; selection bias possible; Japan-specific |
Key quantitative result: Real-world ORR, DCR, time on treatment for T-DXd and other HER2-directed agents (specific values not reported in abstract).
Main limitation: Abstract truncated — specific outcome data not extractable. Japanese-only population; may not generalize to Western treatment patterns. Retrospective database design.
Equity implications: C-CAT database is unusually high-quality but Japan-specific; underrepresents racial/ethnic minorities globally. HER2-mutant NSCLC testing access is variable internationally.
Evidence Maturity Confirmation: ✅ Validated (real-world) — though medium classification_confidence warrants full-text review.
Article 4 — Wang et al. — Low-dose IL-2 for irAE via Tfh/Treg
PMID: 42262537 | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First prospective transcriptomic characterization of Tfh/Treg imbalance as early irAE predictor; LDIL-2 repurposing in this context is a novel mechanistic hypothesis |
| Clinical Relevance | 6 | irAE management is a major bottleneck in immunotherapy; concept is compelling but human cohort is too small (n=26) to change practice |
| Population Reach | 7 | Anti-PD-1/PD-L1 is used across virtually all solid tumor types; irAEs affect 60–70% of patients; scope is enormous if validated |
| Implementation Speed | 3 | Preclinical translation stage; requires prospective RCT before clinical adoption; LDIL-2 is established but irAE indication is novel |
| Evidence Strength | 5 | Prospective human component adds credibility; n=26 is underpowered; murine model supports mechanism but is not human validation |
Key quantitative result: Tfh/Treg ratio significantly higher in irAE patients (p<0.001); IL-21 and PDCD1 upregulation p<0.01–0.05; murine LDIL-2 preserved antitumor efficacy while reducing inflammatory lesions.
Main limitation: n=26 human cohort; mixed model study; GI cancer-specific — may not generalize across tumor types or checkpoint inhibitor classes.
Equity implications: irAE management access is already inequitable; a low-cost repurposed agent (LDIL-2) could be advantageous in lower-resource settings if validated.
Evidence Maturity Confirmation: ✅ Exploratory — strong rationale but clearly early stage.
Article 5 — Rosellini et al. — KIM-1 and biomarkers in adjuvant ccRCC
PMID: 42261901 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | KIM-1 in RCC is not new; the integrative framework combining KIM-1, ctDNA, PBRM1/BAP1 is a useful synthesis but not original discovery |
| Clinical Relevance | 5 | Clinical gap is real (adjuvant therapy selection in ccRCC is unsolved); but no new prospective data — expert opinion only |
| Population Reach | 5 | ~80K kidney cancer diagnoses/year in US; high-risk resected ccRCC is a defined subset |
| Implementation Speed | 3 | No validated biomarker ready for clinical use; KIM-1 assays exist but not prospectively validated for this indication |
| Evidence Strength | 3 | Expert review without new primary data; IMmotion010 subset is exploratory; no prospective validation |
Main limitation: Pure review — no original data; no validated clinical decision tool produced.
Evidence Maturity Confirmation: ✅ Exploratory.
Article 6 — Lin et al. — Spatial transcriptomics insufficient RFA in HCC
PMID: 42263221 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Visium HD spatial transcriptomics on FFPE clinical tissue revealing CEBPD/CXCL2/SPP1+ TAM axis is mechanistically novel and technically advanced |
| Clinical Relevance | 4 | Relevant clinical problem (RFA recurrence) but primarily preclinical; CXCR2 inhibitors not yet validated in this context; human n=6 |
| Population Reach | 6 | HCC affects ~900K/year globally; RFA is used in ~40% of HCC patients; recurrence is a near-universal problem |
| Implementation Speed | 2 | Early-stage mechanistic discovery; CXCR2 inhibitor trials would require years |
| Evidence Strength | 4 | Impressive technology but human cohort is n=6; non-human model cap applies; primarily preclinical |
Cap applied: Non-human models are primary mechanistic engine; Clinical Relevance capped at 4 per rubric.
Evidence Maturity Confirmation: ✅ Exploratory.
Article 7 — Portela et al. — AF with BiTE therapy FAERS
PMID: 42263195 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AF signal with BiTEs is not entirely unexpected (cytokine biology); epcoritamab and mosunetuzumab-specific signals add specificity to existing suspicion |
| Clinical Relevance | 7 | Directly actionable: cardiac monitoring protocols for epcoritamab/mosunetuzumab should be updated; both are approved and rapidly expanding in use |
| Population Reach | 5 | B-cell lymphoma patients receiving BiTE therapy — growing population as epcoritamab/mosunetuzumab expand to earlier lines |
| Implementation Speed | 8 | Pharmacovigilance data; no regulatory change needed — clinician awareness and monitoring protocol update can happen immediately |
| Evidence Strength | 5 | Large denominator (11M FAERS reports) but disproportionality analysis is hypothesis-generating, not confirmatory; reporting bias is inherent |
Key quantitative result: Overall BiTE ROR 1.28 (95% CI 1.04–1.57); epcoritamab ROR 2.95; mosunetuzumab ROR 3.88.
Evidence Maturity Confirmation: ✅ Validated (pharmacovigilance level — association, not causation).
Article 8 — Li et al. — Hemoglobin-Creatinine Ratio and HF readmission
PMID: 42263346 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | HBCR as a composite is not a fundamentally new concept; anemia and renal dysfunction in HF are well-known; the specific ratio formulation adds marginal novelty |
| Clinical Relevance | 6 | Readily calculable from standard labs; 41% readmission risk reduction in highest tertile is clinically meaningful; needs external validation |
| Population Reach | 8 | Heart failure affects 64M people globally; readmission is a universal quality metric in virtually every health system |
| Implementation Speed | 6 | Zero additional cost tool; needs external validation before formal adoption but could be used informally immediately |
| Evidence Strength | 5 | Single-center Chinese retrospective cohort, n=1,833; aHR 0.80 is robust but external validation needed; abstract only |
Key quantitative result: aHR 0.80 per 1-SD HBCR increase (95% CI 0.71–0.90); highest vs lowest tertile aHR 0.59 (95% CI 0.48–0.73).
Equity implications: Chinese single-center — may not generalize to populations with different baseline HF etiology (e.g., ischemic-dominant Western populations). Populations with high rates of CKD+anemia (Black Americans, South Asians) may show different HBCR distributions.
Evidence Maturity Confirmation: ✅ Validated (single-center; needs external replication before clinical adoption).
Article 9 — Stratigos et al. — European CSCC Treatment Guideline 2026
PMID: 42263355 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Guideline codification of cemiplimab use; not novel science — formalizes existing RCT evidence |
| Clinical Relevance | 8 | High-authority guideline (EADO/EDF/ESTRO/EORTC) directly shapes European clinical practice for a common and growing cancer |
| Population Reach | 7 | CSCC is the second most common skin cancer; incidence rising with aging population; immunosuppressed transplant patients are disproportionately affected |
| Implementation Speed | 9 | Already in practice — guideline update accelerates adoption of adjuvant/neoadjuvant cemiplimab |
| Evidence Strength | 6 | Consensus guideline — highest translation level but not original RCT data; design quality reflects systematic evidence review by expert panel |
Key finding: 50–70% major pathologic response rates with neoadjuvant anti-PD-1; cemiplimab standard first-line for advanced CSCC.
Equity implications: Guideline is European-focused; cemiplimab access varies significantly by country reimbursement policies; immunosuppressed transplant patients (high CSCC risk) face additional complexity.
Evidence Maturity Confirmation: ✅ Validated (practice-level).
Article 10 — Lal et al. — ML analysis emergency CRC resection
PMID: 42263377 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | SDOH-stratified analysis of ECCR is a useful but incremental contribution; insurance as dominant driver in young patients is known but not previously quantified at this scale |
| Clinical Relevance | 6 | Actionable for health policy; not directly actionable at bedside but supports targeted screening/prevention program design |
| Population Reach | 8 | CRC is 3rd most common cancer globally; ECCR affects ~12.6% of 150K+ annual US CRC surgeries; Medicaid/uninsured populations are specifically identified |
| Implementation Speed | 5 | Policy-level interventions (insurance expansion) face systemic barriers; clinical workflow changes are more immediate |
| Evidence Strength | 6 | Large NIS cohort (n=510,135) is robust; CART is descriptive/explanatory rather than prospectively validated predictor; retrospective design |
Equity implications: Core equity finding — uninsured/Medicaid status drives ECCR in adults <75, directly implicating access barriers. Female sex and higher income are protective. This study directly quantifies structural inequity in cancer surgery outcomes.
Evidence Maturity Confirmation: ✅ Validated (descriptive/policy-relevant).
Article 11 — Pizarro-Galleguillos et al. — UMAP muscle MRI myopathies
PMID: 42263369 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | UMAP applied to muscle MRI pattern recognition in neuromuscular disease is novel; 10 myopathies at this scale is the largest such validation |
| Clinical Relevance | 6 | Rare diseases with multi-year diagnostic delay; 87% top-3 accuracy is clinically useful as a decision-support tool |
| Population Reach | 5 | Rare diseases individually (~1:10,000–1:100,000 each) but collectively NMD affects ~160K in the US; relative to affected population, impact is high |
| Implementation Speed | 5 | Requires muscle MRI (available in many centers) and computational pipeline (not yet packaged for clinical deployment) |
| Evidence Strength | 6 | Multicenter n=975 across 10 genetically confirmed myopathies is strong for the rare disease context; UMAP comparison to alternatives is methodologically sound |
Equity implications: Rare neuromuscular disease diagnosis is heavily concentrated in specialized academic centers. This tool could help non-specialist radiologists in community settings — but access to muscle MRI itself remains a barrier globally.
Evidence Maturity Confirmation: ✅ Validated (for the diagnostic algorithm; clinical deployment validation not yet done).
Article 12 — Rubens et al. — Care patterns older MM patients NCDB
PMID: 42263372 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Underutilization of intensive MM therapy in elderly is a known concern; NCDB confirmation adds scale but not new mechanistic insight |
| Clinical Relevance | 7 | Directly challenges age-based treatment restrictions; median OS 64.2 months with C+H+I vs shorter with less intensive regimens is practice-relevant |
| Population Reach | 6 | Median age at MM diagnosis is ~69; the majority of ~35K annual US MM diagnoses fall in this age range |
| Implementation Speed | 6 | No new drug needed — better application of existing regimens; barrier is physician/patient perception of treatability |
| Evidence Strength | 5 | Large NCDB retrospective (likely several thousand patients); significant selection bias (fitter patients selected for intensive therapy); sample size not stated in abstract |
Key quantitative result: C+H+I: median OS 64.2 months, HR 0.575 vs comparator.
Equity implications: NCDB includes facility-level data that typically reveals racial and insurance-based treatment disparities; whether age-based underutilization intersects with race/ethnicity is not stated in abstract but is a likely important dimension.
Evidence Maturity Confirmation: ✅ Validated (retrospective; selection bias is the primary caveat).
Article 13 — Digital Health Interventions SR/MA
PMID: 42263266 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Digital health for chronic disease is well-studied; novelty depends heavily on specific interventions and outcomes analyzed — abstract truncated |
| Clinical Relevance | 6 | Broad applicability to HF, T2DM, COPD; but abstract truncation prevents scoring specific effect sizes |
| Population Reach | 9 | Chronic diseases affect >50% of adults globally; this is among the highest possible population reaches |
| Implementation Speed | 6 | Digital health tools are widely available; implementation barriers are workflow integration, reimbursement, and digital literacy |
| Evidence Strength | 6 | SR+MA of RCTs is the highest evidence design; medium classification_confidence due to truncated abstract — specific outcomes unknown |
Main limitation: Abstract truncated — effect sizes, number of included studies, and specific outcomes not available. Downgraded from potential 7–8 on multiple dimensions due to this constraint.
Equity implications: Digital health interventions can widen the digital divide; older, lower-income, and rural populations may have reduced access to or efficacy from digital self-care tools.
Evidence Maturity Confirmation: ✅ Validated (study design), but incomplete abstract prevents full confirmation.
Article 14 — Mennillo et al. — Spatial transcriptomics FFPE UC/IBD
PMID: 42262875 | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Xenium-based iSCST on routine FFPE biopsies (not fresh-frozen) is a genuine technical and biological advance; two mechanistically distinct VDZ non-responder archetypes is a novel finding |
| Clinical Relevance | 5 | IBD is not a primary oncology topic; vedolizumab resistance is clinically important (~30–40% primary non-response) but clinical applicability is 5–10 years away |
| Population Reach | 6 | UC affects ~3M in the US alone; vedolizumab is widely used; but the spatial transcriptomics platform limits immediate reach |
| Implementation Speed | 3 | Xenium panels on clinical FFPE biopsies are technically demanding; not yet clinical-grade implementation |
| Evidence Strength | 6 | JCI-published with internal + external dataset validation; sample size not reported; technically rigorous |
Evidence Maturity Revision: ⬇️ Triage classified as Exploratory — confirmed. High novelty but early-stage clinical translation.
Article 15 — Ma et al. — Lenvatinib+atezolizumab liver transplant HCC
PMID: 42262196 | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Immunotherapy in transplant recipients is genuinely novel territory; ctDNA monitoring component adds value; OS 36 months is noteworthy |
| Clinical Relevance | 5 | High unmet need population but n=15 is insufficient for clinical guidance; lower-impact journal; medium classification_confidence |
| Population Reach | 4 | Liver transplant recipients with HCC recurrence is a small population (~3–5K/year in US) |
| Implementation Speed | 3 | Requires validation in larger studies; immunosuppression management complexity is a major practical barrier |
| Evidence Strength | 3 | n=15 retrospective single-center; lower-impact journal (Pakistan J Pharm Sci) |
Evidence Maturity Confirmation: ✅ Exploratory — n=15 is hypothesis-generating only.
Article 16 — Zhong et al. — FeatStainDiff H&E-to-IHC diffusion model
PMID: 42263351 | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Feature-level (not pixel-level) diffusion for stain translation is a novel architectural approach; Contrastive Semantic Bridging + FMoE is original |
| Clinical Relevance | 4 | Promising for resource-limited pathology access but no prospective clinical validation; currently benchmark datasets only |
| Population Reach | 5 | Global pathology access gap affects billions; but implementation runway is long |
| Implementation Speed | 3 | Code not yet released; clinical validation not performed; regulatory pathway undefined |
| Evidence Strength | 4 | Technical validation on public benchmarks; no clinical dataset performance; no prospective study |
Evidence Maturity Confirmation: ✅ Exploratory.
Article 17 — Rugo et al. — ET suitability HR+ MBC framework
PMID: 42263382 | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Reframing ET resistance as "ET suitability" is conceptually useful but not a discovery; ESR1/PIK3CA biomarkers are well-established |
| Clinical Relevance | 6 | HR+/HER2- MBC is the largest breast cancer subtype; clarifying treatment sequencing has practical value for oncologists |
| Population Reach | 7 | HR+ MBC accounts for ~70% of metastatic breast cancer diagnoses — very large affected population |
| Implementation Speed | 4 | Framework concept only; no new validated tools; AstraZeneca funding and COI should be noted |
| Evidence Strength | 3 | Expert opinion, no primary data; industry-funded; COI declared |
COI flag: All authors report AstraZeneca-funded publication; independent assessment of framework claims warranted.
Evidence Maturity: Designated Validated by OpenClaw — I revise this to Exploratory/Conceptual given no new data and heavy industry funding bias.
Article 18 — Patharkar et al. — H2C healthy reference curation ML
PMID: 42263371 | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Self-tuned KDE-based healthy subset curation is a methodologically sound and underexplored problem; F1 improvements across three domains are consistent |
| Clinical Relevance | 3 | Indirect — improves ML classifier performance upstream; no direct patient impact yet |
| Population Reach | 4 | Broad potential across any ML diagnostic system; but indirect and distant |
| Implementation Speed | 4 | Classifier-agnostic approach is practically accessible; needs clinical integration |
| Evidence Strength | 4 | Public benchmark datasets only; no prospective clinical validation |
Evidence Maturity Confirmation: ✅ Exploratory.
Articles 19 & 20 — Case Reports (pipeline_ready = false)
Singh et al. — Absent BME MRI in MM VCF | PMID: 42263284 | Triage: 2 Memon — CLL leukemia cutis | PMID: 42261453 | Triage: 1
Both are excluded from ranking per pipeline_ready=false designation. Scores not materially different from Phase 1 triage: single case reports, minimal novelty, no population-level impact.
PHASE 3 — Ranking
Conflicting Literature Notes
No direct conflicts across this batch. However, two articles address complementary dimensions of the same challenge (early detection in poor-prognosis cancers): Articles 1 (ctDNA in UC, established biomarker class) and 2 (bile exosomal miRNA in BTC, emerging biomarker route) represent convergent but non-competing approaches.
Articles 3 and 17 both address real-world precision oncology decision-making in different tumor types; no direct conflict but different evidence quality tiers.
Composite Impact Score Calculation
Weighting: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%
| Rank | Article (PMID) | Clin Rel (×0.30) | Pop Reach (×0.25) | Sci Nov (×0.20) | Impl Speed (×0.15) | Evid Str (×0.10) | Composite | Triage Score | Flag |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ctDNA UC SR (42262988) | 8×0.30=2.40 | 6×0.25=1.50 | 7×0.20=1.40 | 7×0.15=1.05 | 7×0.10=0.70 | 7.05 | 8 | 🔴 |
| 2 | CSCC Guideline 2026 (42263355) | 8×0.30=2.40 | 7×0.25=1.75 | 3×0.20=0.60 | 9×0.15=1.35 | 6×0.10=0.60 | 6.70 | 6 | 🟢 |
| 3 | Bile miRNA BTC (42261877) | 7×0.30=2.10 | 5×0.25=1.25 | 8×0.20=1.60 | 4×0.15=0.60 | 6×0.10=0.60 | 6.15 | 8 | 🔴 |
| 4 | HER2 NSCLC Japan (42263332) | 7×0.30=2.10 | 5×0.25=1.25 | 5×0.20=1.00 | 7×0.15=1.05 | 5×0.10=0.50 | 5.90 | 7 | 🟢 |
| 5 | BiTE AF FAERS (42263195) | 7×0.30=2.10 | 5×0.25=1.25 | 5×0.20=1.00 | 8×0.15=1.20 | 5×0.10=0.50 | 6.05 | 6 | 🟢 |
| 6 | Emergency CRC ML (42263377) | 6×0.30=1.80 | 8×0.25=2.00 | 5×0.20=1.00 | 5×0.15=0.75 | 6×0.10=0.60 | 6.15 | 6 | 🟡 |
| 7 | LDIL-2 irAE (42262537) | 6×0.30=1.80 | 7×0.25=1.75 | 8×0.20=1.60 | 3×0.15=0.45 | 5×0.10=0.50 | 6.10 | 7 | 🟠 |
| 8 | Older MM NCDB (42263372) | 7×0.30=2.10 | 6×0.25=1.50 | 4×0.20=0.80 | 6×0.15=0.90 | 5×0.10=0.50 | 5.80 | 6 | 🟡 |
| 9 | Digital Health SR/MA (42263266) | 6×0.30=1.80 | 9×0.25=2.25 | 3×0.20=0.60 | 6×0.15=0.90 | 6×0.10=0.60 | 6.15 | 6 | 🟢 |
| 10 | HBCR Heart Failure (42263346) | 6×0.30=1.80 | 8×0.25=2.00 | 5×0.20=1.00 | 6×0.15=0.90 | 5×0.10=0.50 | 6.20 | 6 | 🟢 |
| 11 | UMAP Myopathy MRI (42263369) | 6×0.30=1.80 | 5×0.25=1.25 | 6×0.20=1.20 | 5×0.15=0.75 | 6×0.10=0.60 | 5.60 | 6 | 🟡 |
| 12 | Spatial Tx HCC RFA (42263221) | 4×0.30=1.20 | 6×0.25=1.50 | 8×0.20=1.60 | 2×0.15=0.30 | 4×0.10=0.40 | 5.00 | 6 | ⚪ |
| 13 | Spatial Tx FFPE UC (42262875) | 5×0.30=1.50 | 6×0.25=1.50 | 8×0.20=1.60 | 3×0.15=0.45 | 6×0.10=0.60 | 5.65 | 6 | ⚪ |
| 14 | KIM-1 ccRCC review (42261901) | 5×0.30=1.50 | 5×0.25=1.25 | 5×0.20=1.00 | 3×0.15=0.45 | 3×0.10=0.30 | 4.50 | 6 | ⚪ |
| 15 | HR+ MBC ET suitability (42263382) | 6×0.30=1.80 | 7×0.25=1.75 | 3×0.20=0.60 | 4×0.15=0.60 | 3×0.10=0.30 | 5.05 | 5 | ⬜ |
| 16 | Lenvatinib+atezo transplant HCC (42262196) | 5×0.30=1.50 | 4×0.25=1.00 | 5×0.20=1.00 | 3×0.15=0.45 | 3×0.10=0.30 | 4.25 | 5 | ⚪ |
| 17 | FeatStainDiff H&E-IHC (42263351) | 4×0.30=1.20 | 5×0.25=1.25 | 7×0.20=1.40 | 3×0.15=0.45 | 4×0.10=0.40 | 4.70 | 5 | ⚪ |
| 18 | H2C ML curation (42263371) | 3×0.30=0.90 | 4×0.25=1.00 | 6×0.20=1.20 | 4×0.15=0.60 | 4×0.10=0.40 | 4.10 | 4 | ⬜ |
Articles 19 and 20 excluded (pipeline_ready = false).
Tie-breaking applied:
- Articles 3 (Bile miRNA, 6.15), 6 (Emergency CRC, 6.15), 9 (Digital Health, 6.15) scored identically at composite 6.15. Tie-broken by Clinical Relevance: Bile miRNA (7) > Emergency CRC (6) = Digital Health (6). For Emergency CRC vs Digital Health: Evidence Strength both 6; Implementation Speed: Emergency CRC (5) < Digital Health (6) — Digital Health ranks above Emergency CRC.
- Articles 5 (BiTE AF, 6.05) and 7 (LDIL-2, 6.10) — LDIL-2 ranks above BiTE AF.
Adjusted Final Ranking Table
| Rank | Article | Impact Score | Triage Score | Clin Rel | Pop Reach | Sci Nov | Impl Spd | Evid Str | Study Design | Flag |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ctDNA UC SR (42262988) | 7.05 | 8 | 8 | 6 | 7 | 7 | 7 | Systematic review (61 studies) | 🔴 |
| 2 | CSCC Guideline 2026 (42263355) | 6.70 | 6 | 8 | 7 | 3 | 9 | 6 | Expert consensus guideline | 🟢 |
| 3 | Bile miRNA BTC (42261877) | 6.15 | 8 | 7 | 5 | 8 | 4 | 6 | Multi-cohort validation study | 🔴 |
| 4 | Digital Health SR/MA (42263266) | 6.15 | 6 | 6 | 9 | 3 | 6 | 6 | SR + meta-analysis of RCTs | 🟢 |
| 5 | Emergency CRC ML (42263377) | 6.15 | 6 | 6 | 8 | 5 | 5 | 6 | Retrospective cohort + CART ML | 🟡 |
| 6 | HBCR Heart Failure (42263346) | 6.20 | 6 | 6 | 8 | 5 | 6 | 5 | Retrospective cohort | 🟢 |
| 7 | LDIL-2 irAE (42262537) | 6.10 | 7 | 6 | 7 | 8 | 3 | 5 | Prospective cohort + murine | 🟠 |
| 8 | BiTE AF FAERS (42263195) | 6.05 | 6 | 7 | 5 | 5 | 8 | 5 | FAERS disproportionality | 🟢 |
| 9 | HER2 NSCLC Japan (42263332) | 5.90 | 7 | 7 | 5 | 5 | 7 | 5 | Retrospective cohort (nationwide DB) | 🟢 |
| 10 | Older MM NCDB (42263372) | 5.80 | 6 | 7 | 6 | 4 | 6 | 5 | Retrospective cohort (NCDB) | 🟡 |
| 11 | UMAP Myopathy MRI (42263369) | 5.60 | 6 | 6 | 5 | 6 | 5 | 6 | Multicenter validation study | 🟡 |
| 12 | Spatial Tx FFPE UC (42262875) | 5.65 | 6 | 5 | 6 | 8 | 3 | 6 | Translational (iSCST + ext. validation) | ⚪ |
| 13 | Spatial Tx HCC RFA (42263221) | 5.00 | 6 | 4 | 6 | 8 | 2 | 4 | Translational (spatial Tx + preclinical) | ⚪ |
| 14 | HR+ MBC ET suitability (42263382) | 5.05 | 5 | 6 | 7 | 3 | 4 | 3 | Expert review/opinion (industry-funded) | ⬜ |
| 15 | KIM-1 ccRCC review (42261901) | 4.50 | 6 | 5 | 5 | 5 | 3 | 3 | Expert review | ⚪ |
| 16 | FeatStainDiff H&E-IHC (42263351) | 4.70 | 5 | 4 | 5 | 7 | 3 | 4 | Technical validation study | ⚪ |
| 17 | Lenvatinib+atezo transplant HCC (42262196) | 4.25 | 5 | 5 | 4 | 5 | 3 | 3 | Retrospective cohort n=15 | ⚪ |
| 18 | H2C ML curation (42263371) | 4.10 | 4 | 3 | 4 | 6 | 4 | 4 | Technical/methodological study | ⬜ |
Rank Justifications (Top 5)
#1 — ctDNA in Urothelial Carcinoma (PMID 42262988) 🔴 This systematic review of 61 studies earns the top position by delivering the only true stage-spanning clinical integration framework in the batch. The HR 6.3 for post-surgery ctDNA positivity (from IMvigor010) is one of the strongest prognostic effect sizes in the batch, and the 94–100% sensitivity with 96–131 day lead time for recurrence monitoring directly informs surveillance protocol design. Clinical Relevance (8) and Evidence Strength (7) both exceed the threshold for #1 ranking. The breadth of synthesized evidence across NMIBC, MIBC, and metastatic UC gives this immediate multi-setting applicability. The framework is ready for integration into institutional protocols now.
Why it matters: This is the roadmap clinicians and trialists have been waiting for — ctDNA in bladder cancer is no longer a collection of fragmented trial subsets but a coherent evidence base with stage-specific clinical strategies.
#2 — CSCC European Treatment Guideline 2026 (PMID 42263355) 🟢 High-authority guideline from EADO/EDF/ESTRO/EORTC earns second place primarily through exceptional Implementation Speed (9) and strong Clinical Relevance (8). Cemiplimab as standard first-line for advanced CSCC is already approved; this guideline formalizes adjuvant and neoadjuvant indications and mandates multidisciplinary care. CSCC incidence is rising globally, particularly in immunosuppressed populations (transplant recipients, hematologic malignancy patients), making this guideline's reach broader than commonly appreciated.
Why it matters: For dermatologists and oncologists managing advanced skin cancer, this is the updated blueprint — neoadjuvant anti-PD-1 achieving 50–70% pathologic response rates is now formally endorsed practice.
#3 — Bile exosomal miRNA in BTC (PMID 42261877) 🔴 Ranks third on Scientific Novelty (8) and Clinical Relevance (7), held back only by Implementation Speed (4) due to the ERCP requirement. The core finding — that bile-derived exosomal miR-196a detects early-stage biliary tract cancer with AUROC 0.88 in combination with CA19-9+CEA — addresses a genuine unmet need in one of oncology's most lethal and late-diagnosed cancers. The multi-cohort validation design (n=203 across three independent cohorts) provides credible early-stage evidence.
Why it matters: Biliary tract cancer kills most patients within a year of diagnosis because it is rarely caught early. A bile-based biomarker detectable at early stage — combined with existing clinical markers — offers a realistic pathway to meaningful survival improvement if validated at scale.
#4 — Digital Health Interventions SR/MA (PMID 42263266) 🟢 Earns fourth place through exceptional Population Reach (9) — chronic diseases including HF and T2DM collectively affect the majority of adults globally. The SR+MA of RCTs design is the strongest evidence tier in the batch alongside Article 1. However, the abstract truncation is a critical limitation that prevents scoring of specific effect sizes, and the novelty in this well-studied space is low (3). Full-text review is strongly recommended before acting on this ranking.
Why it matters: With chronic disease self-management costing health systems trillions annually, even modest effect sizes across this population represent enormous absolute benefit if scalable digital interventions can reliably deliver them.
#5 (tie) — Emergency CRC resection ML analysis (PMID 42263377) 🟡 A 510,135-patient NIS analysis revealing that insurance status — not clinical complexity — dominates emergency CRC surgery risk in adults under 75 is a clear and actionable policy finding. The equity implications are direct and quantified, which is relatively rare. Implementation requires policy action rather than clinical protocol change, which somewhat limits immediate impact, but the evidence base is robust and the public health urgency is high.
Why it matters: Emergency surgery carries 3–5× the mortality of elective surgery. If insurance gaps are the dominant driver in younger patients, the intervention is political and economic, not just medical — and this study provides the evidence to make that case.